MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder

D. Nolasco, L. Schmidt, B. Carr (Gainesville, USA)

Meeting: 2024 International Congress

Abstract Number: 382

Keywords: Antidepressants, Depression, Parkinson’s

Category: Parkinson's Disease: Psychiatric Manifestations

Objective: This investigation delineates the pharmacokinetic intricacies encountered in the therapeutic management of a geriatric patient with Parkinson’s Disease (PD) concomitantly suffering from refractory Major Depressive Disorder (MDD), with a specific focus on the drug interaction between paroxetine and ziprasidone.

Background: The case study probes into the treatment of a geriatric patient with PD, further complicated by refractory MDD. The initial regimen of ziprasidone for PD-related apathy yielded modest improvements. However, the addition of paroxetine presents a paradigmatic example of the complexities inherent in neuropsychiatric comorbidity management within PD, spotlighting the quintessential pharmacokinetic challenges, viz a viz-risks.

Method: An analysis was conducted on the pharmacokinetic entanglement precipitated by the integration of paroxetine into the existing ziprasidone regimen by the neurologic care team. This study emphasizes the emergent QTc interval prolongation and explores its ramifications within the ambit of PD and MDD co-management.

Results: Subsequent to paroxetine incorporation, a rapid, pronounced QTc interval prolongation (>550 ms) was observed. While a direct causative link to the cardiac anomaly remains speculative, the temporal association with the pharmacotherapeutic adjustment suggests a potential elevation in ziprasidone plasma levels, potentially mediated by paroxetine-induced CYP2D6 enzymatic inhibition.

Conclusion: This underscores the imperative for meticulous, informed pharmacological decision-making in the realm of geriatric neurology, especially amidst psychiatric comorbidities. It emphasizes the critical need for physicians to possess acute awareness of complex pharmacokinetic interactions, championing the ethos of interdisciplinary collaboration to preempt adverse drug interactions. This discourse significantly enriches the conversation on refining neuropharmacological approaches, with a paramount focus on patient safety and optimizing treatment outcomes in the delicate nature of geriatric patient care.

To cite this abstract in AMA style:

D. Nolasco, L. Schmidt, B. Carr. Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/pharmacokinetic-intersections-in-geriatric-neuropharmacology-a-parkinsons-disease-case-study-with-concomitant-refractory-major-depressive-disorder/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/pharmacokinetic-intersections-in-geriatric-neuropharmacology-a-parkinsons-disease-case-study-with-concomitant-refractory-major-depressive-disorder/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley